^
Association details:
Biomarker:ATRX deletion
Cancer:Glioma
Drug:Talzenna (talazoparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity

Excerpt:
U251 and LN229 glioma cells...We then validated the differential PARP inhibitor sensitivity in our U251 line containing ATRX shRNA. Upon ATRX knockdown, U251 cells show sensitivity to olaparib...and BMN-673...loss of ATRX confers significant sensitivity to PARP inhibitors.
DOI:
https://doi.org/10.1016/j.tranon.2021.101147